Alpha Tau Medical Shares Rally After Brain Cancer Treatment Shows Complete Tumor Clearance in Trial
Alpha Tau Medical shares jumped 15.70% in premarket trading after reporting that its Alpha DaRT therapy achieved complete tumor clearance in five out of six evaluable patients with recurrent glioblastoma in an ongoing U.S. trial.
💳Personal FinancePhoto: Benzinga
Key points
- Alpha Tau Medical shares rose 15.70% in premarket trading to $15.48.
- Five out of six evaluable brain cancer patients achieved complete tumor clearance.
- All eight trial participants remained alive with no unanticipated serious adverse events.
Alpha Tau Medical Ltd. shares climbed 15.70% to $15.48 in premarket trading on Monday following positive interim data from its U.S. clinical trial evaluating Alpha DaRT therapy for recurrent glioblastoma, a severe form of brain cancer. For everyday investors tracking medical technology equities, the sharp upward move brings the stock close to its 52-week high of $15.79.
According to trial data capturing patient outcomes through November 11, clinicians have treated eight patients, with six reaching the MRI response assessment stage. All six evaluable participants achieved an objective response under RANO criteria. Notably, five patients, representing 83.3% of the assessed group, demonstrated complete tumor clearance with no measurable disease remaining at the treated site. An additional patient experienced a partial response with a 58% tumor size reduction.
Researchers reported favorable safety outcomes alongside the tumor response rates. All eight treated patients remained alive as of the November cutoff, with a median follow-up of 6.9 months for the assessed cohort. Investigators successfully deployed the therapy in 100% of cases and noted no unanticipated serious adverse events, though one patient experienced a previously documented grade 3 seizure that resolved with treatment.
What to watch next: Enrollment in the trial continues toward a target of 20 patients, with ongoing imaging required to confirm early responses in newer participants and monitor for potential recurrence.
Source Benzinga — benzinga.com/markets/biotech/26/11/63291764/alpha-dart-therapy-show… ↗
Read next
🧠AI AnalysisWalmart Shares Waver Despite Topping Estimates as Growth Momentum Cools
Walmart posted third-quarter results that surpassed analyst expectations, though slower growth rates across key segments prompted market hesitation before the stock recov…
🧠AI AnalysisBitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold
Bitcoin recently traded around $59,090 following a decisive breakdown below the crucial $62,000–$64,000 support zone, shifting short-term market momentum toward sellers.
🧠AI AnalysisBitcoin Tests Support Following Drop Below $60,000 Milestone
Bitcoin recently swept the $55,000 mark before rebounding toward the $59,100 region following a sharp decline that broke previous support levels on November 20.
🧠AI AnalysisEvaluating HF Sinclair and the Turning Oil Refining Cycle
HF Sinclair has experienced impressive expansion driven largely by its refining sector, but market observers suggest the cyclical peak may be near.
🧠AI AnalysisBitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce
Bitcoin remains constrained by a broader bearish pattern on short-term charts as dynamic trendline resistance caps recovery attempts. Although price recently rebounded fr…
🧠AI AnalysisMapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises
A breakdown of a $500 allocation into Infleqtion and Xanadu reveals the high-risk, high-reward nature of early-stage quantum computing investments.